Overview

A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Status:
Terminated
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to see how GLPG1690 works together with the current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug).
Phase:
Phase 3
Details
Lead Sponsor:
Galapagos NV